These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8558750)

  • 1. Effect of the initial bolus volume of recombinant tissue-type plasminogen activator on coronary recanalization and infarct size in Japanese acute myocardial infarction patients. Kumamoto University Myocardial Infarction Study (KUMIS) Group.
    Ogawa H; Yasue H; Oshima S; Ogata Y; Numata Y; Fujimoto K; Imoto N; Saito T; Hokamura Y; Takahashi T
    Jpn Circ J; 1995 Oct; 59(10):663-72. PubMed ID: 8558750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early coronary reperfusion blunts the procoagulant response of plasminogen activator inhibitor-1 and von Willebrand factor in acute myocardial infarction.
    Andreotti F; Roncaglioni MC; Hackett DR; Khan MI; Regan T; Haider AW; Davies GJ; Kluft C; Maseri A
    J Am Coll Cardiol; 1990 Dec; 16(7):1553-60. PubMed ID: 2123906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of multiple bolus administration of tissue-type plasminogen activator in acute myocardial infarction.
    Khan MI; Hackett DR; Andreotti F; Davies GJ; Regan T; Haider AW; McFadden E; Halson P; Maseri A
    Am J Cardiol; 1990 May; 65(16):1051-6. PubMed ID: 2109926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between the door-to-TIMI-3 flow time and the infarct size in patients suffering from acute myocardial infarction: analysis based on the fibrinolysis and subsequent transluminal (FAST-3) trial.
    Watanabe K; Nagao K; Watanabe I; Kanmatsuse K
    Circ J; 2004 Apr; 68(4):280-5. PubMed ID: 15056821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction.
    Gurbel PA; Anderson RD; MacCord CS; Scott H; Serebruany V; Herzog WR
    Coron Artery Dis; 1994 Nov; 5(11):929-36. PubMed ID: 7719525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.
    Collen D; Van de Werf F
    Am J Cardiol; 1987 Sep; 60(7):431-4. PubMed ID: 3115077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarction.
    Tebbe U; Tanswell P; Seifried E; Feuerer W; Scholz KH; Herrmann KS
    Am J Cardiol; 1989 Sep; 64(8):448-53. PubMed ID: 2505604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.
    Smalling RW; Bode C; Kalbfleisch J; Sen S; Limbourg P; Forycki F; Habib G; Feldman R; Hohnloser S; Seals A
    Circulation; 1995 Jun; 91(11):2725-32. PubMed ID: 7758177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrograde coronary venous administration of recombinant tissue-type plasminogen activator: a unique and effective approach to coronary artery thrombolysis.
    Miyazaki A; Tadokoro H; Drury JK; Rydén L; Haendchen RV; Corday E
    J Am Coll Cardiol; 1991 Aug; 18(2):613-20. PubMed ID: 1906906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous recombinant tissue-type plasminogen activator (rt-PA) and urokinase (UK) in patients with evolving myocardial infarction--a multicenter double-blind, randomized trial in Japan.
    Kanemoto N; Goto Y; Hirosawa K; Kawai C; Kimata S; Yui Y; Yamamoto Y
    Jpn Circ J; 1991 Mar; 55(3):250-61. PubMed ID: 1903167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intravenous infusion of recombinant tissue-type plasminogen activator (rt-PA) and urokinase in acute myocardial infarct: intermediate results of the G.A.U.S. study (German Activator Urokinase Study)].
    Neuhaus KL; Tebbe U; Gottwik M; Weber MA; Feuerer W; Niederer W; Haerer W; Praetorius F; Grosser KD; Huhmann W
    Klin Wochenschr; 1988; 66 Suppl 12():102-8. PubMed ID: 3126339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Intravenous recombinant tissue-type plasminogen activator in acute myocardial infarction].
    Gao R
    Zhonghua Xin Xue Guan Bing Za Zhi; 1991 Aug; 19(4):228-30, 267-8. PubMed ID: 1813288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single bolus administration of recombinant tissue plasminogen activator: effects on infarct related vessel patency, microvascular perfusion, and microvascular reocclusion in a canine model of thrombotic occlusion/reperfusion.
    Longridge DJ; Follenfant MJ; Ford AJ
    Cardiovasc Res; 1991 Mar; 25(3):184-91. PubMed ID: 1903080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous recombinant tissue-type plasminogen activator in acute myocardial infarction.
    Gao R; Chen J; Kou W; Yao K; Xu Y; Lu Z; Yu Q; Tao P; Ma J; Zhu J
    Chin Med Sci J; 1991 Sep; 6(3):132-5. PubMed ID: 1793874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiographic study of mutant tissue-type plasminogen activator versus urokinase for acute myocardial infarction.
    Nagao K; Satou K; Watanabe I; Arima K; Yamashita M; Ooiwa K; Kanmatsuse K
    Jpn Circ J; 1998 Feb; 62(2):111-4. PubMed ID: 9559429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue-type plasminogen activator therapy versus primary coronary angioplasty: impact on myocardial tissue perfusion and regional function 1 month after uncomplicated myocardial infarction.
    Agati L; Voci P; Hickle P; Vizza DC; Autore C; Fedele F; Feinstein SB; Dagianti A
    J Am Coll Cardiol; 1998 Feb; 31(2):338-43. PubMed ID: 9462577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of low-dose mutant tissue-type plasminogen activator followed by planned rescue percutaneous transluminal coronary angioplasty as reperfusion therapy for acute myocardial infarction].
    Tsukahara K; Kimura K; Usui T; Okuda J; Kitamura Y; Kosuge M; Sano T; Tohyama S; Nemoto T; Yamanaka O; Yoshii Y; Tochikubo O; Umemura S
    J Cardiol; 2001 Mar; 37(3):143-50. PubMed ID: 11281054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of coronary artery reperfusion with creatine kinase-MB determinations during thrombolytic therapy: correlation with acute angiography.
    Garabedian HD; Gold HK; Yasuda T; Johns JA; Finkelstein DM; Gaivin RJ; Cobbaert C; Leinbach RC; Collen D
    J Am Coll Cardiol; 1988 Apr; 11(4):729-34. PubMed ID: 3127451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a prolonged infusion of recombinant tissue-type plasminogen activator (Duteplase) in preventing reocclusion following successful thrombolysis in acute myocardial infarction.
    Kalbfleisch J; Thadani U; LittleJohn JK; Brown G; Magorien R; Kutcher M; Taylor G; Maddox WT; Campbell WB; Perry J
    Am J Cardiol; 1992 May; 69(14):1120-7. PubMed ID: 1575179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Optimal reperfusion therapy in acute myocardial infarction: time to reperfusion and recanalization rate].
    Mochida Y; Kimura K; Kosuge M; Yoshida K; Iwasawa Y; Hongo Y; Sugiyama M; Ishikawa T; Kuji N; Tochikubo O; Ishii M
    J Cardiol; 1998 May; 31(5):255-62. PubMed ID: 9617655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.